Flunitrazepam

Esōes Cosmetics Smart Safety Beauty Products Now Available for Pre-Sale

Retrieved on: 
Friday, December 2, 2022
Sale, Rape, Woman, Statistics, Safety, Entrepreneurship, Cosmetics, Benzodiazepine, Flunitrazepam, Domestic violence, Ecosystem, Violence, Patent, LAS, Bluetooth

LAS VEGAS, Dec. 2, 2022 /PRNewswire/ -- Esōes Cosmetics is launching the first patent-pending Liquid Lipstick with smart safety features all within the Bluetooth connected product. With the first lipsticks set to ship in early 2023, five different shades of Esōes Cosmetics' Liquid Lipstick are now available for presale at esoescosmetics.com.

Key Points: 
  • With the first lipsticks set to ship in early 2023, five different shades of Eses Cosmetics' Liquid Lipstick are now available for presale at esoescosmetics.com .
  • Eses Cosmetics Liquid Lipsticks are now available for pre-sale.
  • Eses Cosmetics is an ecosystem of solutions anchored in patent pending products and community outreach.
  • Our three pillars are: innovative smart safety cosmetics, a responsive giving model, & education.

Idorsia announces financial results for the first half 2021 – Building momentum towards becoming a fully-fledged biopharmaceutical company

Retrieved on: 
Tuesday, July 27, 2021
Food and Drug Administration, Drugs, Pharmaceutical industry, Health sciences, Health care, Drug Safety, GABAA receptor positive allosteric modulators, Lactams, PMDA, New Drug Application, Flunitrazepam

In April and July of 2020, Idorsia reported positive results in each of the two pivotal Phase 3 studies of daridorexant in patients with insomnia.

Key Points: 
  • In April and July of 2020, Idorsia reported positive results in each of the two pivotal Phase 3 studies of daridorexant in patients with insomnia.
  • Should approval be received, the company anticipates launch in the US in the second quarter of 2022, followed by other regions thereafter.
  • A New Drug Application (NDA) to the Japanese PMDA for clazosentan was submitted on March 1, 2021.
  • Based on initial clinical pharmacology investigation with ACT-541478, the company has decided not to pursue the development of this CNS compound further.

Global Chronic Insomnia Market to 2030 - Insights, Epidemiology, and Market Forecast - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 4, 2021
Health, Pharmaceutical, Sleep disorders, Branches of biology, Psychiatric diagnosis, GABAA receptor positive allosteric modulators, Insomnia, Chronic condition, Medicine, Flunitrazepam, Neuroscience

The "Chronic Insomnia - Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chronic Insomnia - Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • The Chronic Insomnia market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted Chronic Insomnia symptoms market size from 2017 to 2030 segmented by seven major markets.
  • The disease epidemiology covered in the report provides historical as well as forecasted Chronic Insomnia symptoms epidemiology segmented as the Prevalent cases of Chronic Insomnia, Diagnosed Prevalent cases of Chronic Insomnia, Gender-specific cases of Chronic Insomnia, and Age-specific cases of Chronic Insomnia.
  • The chronic insomnia report's drug chapter segment encloses the detailed analysis of Chronic Insomnia early-stage (Phase- I, II, and III) pipeline drugs.

Pear Therapeutics Announces First Participant Enrolled in Virtual Real-World Study of Adults with Chronic Insomnia

Retrieved on: 
Monday, July 13, 2020
Science, Software, Biotechnology, Research, Pharmaceutical, Health, Technology, Clinical trials, Health, GABAA receptor positive allosteric modulators, Chemical compounds, Sleep disorders, Organic compounds, Lactams, Insomnia, Psychiatric diagnosis, RTT, Clinical trial, Flunitrazepam

today announced the first participant enrolled in an open-label, decentralized clinical trial (called the DREAM study) evaluating Somryst, an FDA-authorized prescription digital therapeutic (PDT) for the treatment of chronic insomnia.

Key Points: 
  • today announced the first participant enrolled in an open-label, decentralized clinical trial (called the DREAM study) evaluating Somryst, an FDA-authorized prescription digital therapeutic (PDT) for the treatment of chronic insomnia.
  • The DREAM study will enroll approximately 350 adults in the United States with chronic insomnia for nine weeks of digitally-delivered treatment and collect data in a real-world insomnia population.
  • Pear has developed its own decentralized and fully virtual clinical trial infrastructure for participant recruitment, screening, consent, enrollment, follow up, and progress tracking, which will be used for the DREAM study.
  • The aim of the DREAM study is to further examine the real-world impact of Somryst on chronic insomnia, depression, and anxiety symptoms in patients with chronic Insomnia.

Insights into the Global Insomnia Drugs Market to 2025 - Featuring Astellas Pharma, Flynn Pharma & Pfizer Among Others

Retrieved on: 
Monday, March 30, 2020
Neuroscience, Insomnia, Psychiatric diagnosis, RTT, Flunitrazepam, Sleep, Branches of biology, Psychology

DUBLIN, March 30, 2020 /PRNewswire/ -- The "Insomnia Drugs - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 30, 2020 /PRNewswire/ -- The "Insomnia Drugs - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • The Insomnia Drugs market worldwide is projected to grow by US$1.1 Billion, driven by a compounded growth of 5.2%.
  • Prescription Sleep Aids, one of the segments analyzed and sized in this study, displays the potential to grow at over 4.8%.
  • Poised to reach over US$3.1 Billion by the year 2025, Prescription Sleep Aids will bring in healthy gains adding significant momentum to global growth.

Imbrium Therapeutics Announces First Patient Dosed in Phase 2 Study of Potential First-in-Class Molecule for Insomnia Associated with Alcohol Cessation

Retrieved on: 
Wednesday, October 16, 2019
Health, Other Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, GABAA receptor positive allosteric modulators, RTT, Lactams, Organic compounds, Chemical compounds, Sleep disorders, Hoffmann-La Roche, Insomnia, Neurochemistry, Flunitrazepam, Insomnia Associated with Alcohol Cessation, Imbrium Therapeutics L.P.

Dosing of the first patient in the Phase 2 study of IMB-115 represents an important milestone as we advance our understanding of this molecules potential therapeutic application in insomnia associated with alcohol cessation.

Key Points: 
  • Dosing of the first patient in the Phase 2 study of IMB-115 represents an important milestone as we advance our understanding of this molecules potential therapeutic application in insomnia associated with alcohol cessation.
  • In the Phase 2 study, subjects will receive IMB-115 (1 mg or 2 mg) or placebo, administered orally at bedtime for three weeks.
  • Insomnia is a major challenge for many individuals recovering from alcohol use disorder, which affects approximately half of people experiencing alcohol withdrawal.
  • However, there are no FDA-approved pharmacological treatment options to help these individuals address this potential obstacle to lasting recovery, said Paul Medeiros, president, Imbrium Therapeutics.

United States Insomnia Market and Competitive Landscape Report 2019

Retrieved on: 
Friday, September 6, 2019
Songs, GABAA receptor positive allosteric modulators, RTT, Insomnia, Psychiatric diagnosis, Lactams, Market share, Market analysis, Flunitrazepam

DUBLIN, Sept. 6, 2019 /PRNewswire/ -- The "US Insomnia Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 6, 2019 /PRNewswire/ -- The "US Insomnia Market and Competitive Landscape - 2019" report has been added to ResearchAndMarkets.com's offering.
  • US Insomnia Market and Competitive Landscape Highlights - 2019, provides comprehensive insights into Insomnia pipeline products, Insomnia epidemiology, Insomnia market valuations and forecast, Insomnia drugs sales and competitive landscape in the US.
  • The research is classified into seven sections- Insomnia treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Find out how the market advanced from 2014 and forecast to 2024
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Insomnia products

Insomnia Market to expand at a CAGR of 6.6%, Development of New Drug Formulations to Remain Key Strategy among Pharmaceutical Industries - TMR

Retrieved on: 
Wednesday, August 28, 2019
Sleep disorders, GABAA receptor positive allosteric modulators, Neuroscience, RTT, Psychiatric diagnosis, Insomnia, Lactams, Chemical compounds, Organic compounds, Sleep, Flunitrazepam

Players in the global insomnia market are focusing on the development of cost-effective drugs as cost sensitivity is a key challenge across various regions.

Key Points: 
  • Players in the global insomnia market are focusing on the development of cost-effective drugs as cost sensitivity is a key challenge across various regions.
  • TMRs study forecasts the insomnia market to progress at a CAGR of 6.6% to attain the valuation of US $ 4 Bn by the end of the forecast period.
  • This is mainly because insomnia is one of the most common sleep disorders that affect approximately 34% of the worlds population.
  • The players in the insomnia market are tapping into the potential of the unexplored markets in the developing countries.

Global Insomnia Treatment Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts (2018-2026)

Retrieved on: 
Thursday, September 13, 2018
Sleep, GABAA receptor positive allosteric modulators, Medicine, RTT, Sleep disorders, Clinical medicine, Insomnia, Psychiatric diagnosis, Cognitive behavioral therapy for insomnia, Flunitrazepam, Cognitive behavioral therapy

The "Global Insomnia Treatment Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Insomnia Treatment Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026" report has been added to ResearchAndMarkets.com's offering.
  • The insomnia treatment drugs market pose severe threat from alternative treatment such as cognitive behavioral therapy for insomnia (CBTI) and recent FDA approval of devices such as Fisher Wallace Stimulator and EBB Insomnia Therapy.
  • Currently North America is leading the regional segment for insomnia treatment drugs market.
  • Growing health awareness leading to effective insomnia treatment, and developing healthcare infrastructure drive the market growth in developing nations

Global Market Study on Insomnia Treatment: High Demand for OTC Sleep Aids & OTC Sleep Supplements to Persist

Retrieved on: 
Thursday, July 5, 2018
GABAA receptor positive allosteric modulators, Chemistry, Sleep disorders, Lactams, Psychiatric diagnosis, RTT, Neuroscience, Neurochemistry, Insomnia, Flunitrazepam

LONDON, July 5, 2018 /PRNewswire/ -- This report offers a comprehensive forecast of the global insomnia treatment market between 2018 and 2026.The analysis demonstrates market opportunities and trends in the Global Insomnia Treatment Market, which would further influence the segment.

Key Points: 
  • LONDON, July 5, 2018 /PRNewswire/ -- This report offers a comprehensive forecast of the global insomnia treatment market between 2018 and 2026.The analysis demonstrates market opportunities and trends in the Global Insomnia Treatment Market, which would further influence the segment.
  • The Insomnia Treatment Market segmented as follows:
    This report encompasses the global insomnia treatment market performance in terms of revenue contribution from various segments and also gives an overview of the insomnia sleep disorder, sleep aids and other definitions.
  • Macro-economic factors influencing growth of the insomnia treatment market along with detailing opportunity analysis of market are also outlined.
  • The global insomnia treatment market is segmented based on drug type, distribution channel and region.On the basis of drug type market has been segmented as OTC drugs and prescription drugs.